Biocept - BIOC Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOC shares.
View BIOC analyst ratings or view top-rated stocks.

2 Wall Street analysts have issued 12-month price objectives for Biocept's shares. Their BIOC share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 344.4% from the stock's current price.
View analysts price targets for BIOC or view top-rated stocks among Wall Street analysts.

Biocept's stock was trading at $3.62 on January 1st, 2022. Since then, BIOC stock has decreased by 75.1% and is now trading at $0.9001.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, October 3rd 2022.
View our BIOC earnings forecast.

Biocept, Inc. (NASDAQ:BIOC) announced its quarterly earnings results on Monday, November, 15th. The medical research company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by $0.06. The medical research company earned $17.47 million during the quarter, compared to the consensus estimate of $16.87 million. Biocept had a negative trailing twelve-month return on equity of 19.99% and a negative net margin of 11.26%. During the same quarter in the prior year, the firm posted ($0.43) earnings per share.

Shares of Biocept reverse split before market open on Tuesday, September 8th 2020. The 1-10 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 4th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

4 employees have rated Biocept Chief Executive Officer Michael Nall on Glassdoor.com. Michael Nall has an approval rating of 100% among the company's employees. This puts Michael Nall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Biocept to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biocept investors own include T2 Biosystems (TTOO), iBio (IBIO), VBI Vaccines (VBIV), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Onconova Therapeutics (ONTX), Walmart (WMT), Inovio Pharmaceuticals (INO) and Acasti Pharma (ACST).

Biocept trades on the NASDAQ under the ticker symbol "BIOC."

Biocept's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.04%), Millennium Management LLC (0.61%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David F Hale and David F Hale.
View institutional ownership trends.

Shares of BIOC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BIOC stock can currently be purchased for approximately $0.90.

Biocept (NASDAQ:BIOC) has a market capitalization of $15.23 million and generates $61.25 million in revenue each year. The medical research company earns $-2,820,000.00 in net income (profit) each year or ($0.45) on an earnings per share basis.

The company employs 104 workers across the globe.

Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The official website for the company is www.biocept.com. The medical research company can be reached via phone at (858) 320-8200, via email at ir@biocept.com, or via fax at 858-320-8225.